Calgary, Alberta – TheNewswire - October 11, 2022 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) hosted its first Medical Advisory Board (MAB) meeting on September 29, 2022, prior to the Annual Meeting of the American Academy of Ophthalmology in Chicago, IL.   The MAB will be chaired by Ocumetics’ Chief Medical Officer, Doyle Stulting, MD, PhD, and supported by a group of world renown key external experts who attended the meeting. “This was a significant event for Ocumetics to gather together our potential investigators, as we prepare for the upcoming clinical trials,” said Dr. Mark Lee, CEO of Ocumetics.

The design of the Ocumetics bionic lens was revealed for the first time to ophthalmologists outside of the Company.  A discussion ensued of the potential of the lens for providing both distance and near vision and its ability to rapidly accommodate and disaccommodate.  MAB member, Dr. B. J. Dupps commented, “It was a very stimulating meeting.”

“The Medical Advisory Board provided a fascinating and informative discussion of Ocumetics’ lens technologies, both now and in the future,” said Ocumetics Chief Scientific Officer & Founder, Dr. Garth Webb.  Another MAB member, Dr. Francis Price, Jr, noted “We are fortunate to live in a time where we have access to new technology allowing us to see and function better. For most of human history, people just accepted they would gradually go blind as they grew older.“

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.